Treatment of Relapsed or Primary Refractory Acute Lymphoblastic Leukemia

Clinical Scenario

This protocol addresses patients with acute lymphoblastic leukemia (ALL) who have either failed to achieve remission with initial therapy (primary refractory) or who have relapsed following a prior response. Both situations represent a high-risk population requiring a distinct management approach.

Population

Relapsed or primary refractory ALL (R/R ALL) affects a significant proportion of patients. Depending on the treatment protocol and disease subtype, 5% to 10% of patients will be primary refractory, and an additional 30% to 60% of patients will relapse after achieving an initial remission.

Treatment Approach — Partial Overview

For patients with R/R ALL, the management strategy includes consideration of a transplantation-based intervention as a core component of the plan.

Full regimen details, eligibility criteria, and sequencing available via the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/blood.2023023568

Depending on protocol and subtype, 5% to 10% of patients will be primary refractory, and an additional 30% to 60% of patients will relapse.

SCT indication should be considered in all patients with R/R ALL.

View source ↗